Results of a randomized controlled phase III trial: efficacy of polyphenol-containing cystus® tea mouthwash solution for the reduction of mucositis in head and neck cancer patients undergoing external beam radiotherapy.
Strahlenther Onkol. 2021 Jan;197(1):63-73.
Více informací ZDE
Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.
Lancet Oncol. 2021 Jan;22(1):29-42.
Více informací ZDE
Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A randomised phase III trial.
Eur J Cancer. 2021 Jan;143:64-74.
Více informací ZDE
Randomised trial of external-beam radiotherapy alone or with high-dose-rate brachytherapy for prostate cancer: Mature 12-year results.
Radiother Oncol. 2021 Jan;154:214-219.
Více informací ZDE
ARTSCAN III: A Randomized Phase III Study Comparing Chemoradiotherapy With Cisplatin Versus Cetuximab in Patients With Locoregionally Advanced Head and Neck Squamous Cell Cancer.
J Clin Oncol. 2021 Jan 1;39(1):38-47.
Více informací ZDE
Pre- and Postoperative Capecitabine Without or With Oxaliplatin in Locally Advanced Rectal Cancer: PETACC 6 Trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD.
J Clin Oncol. 2021 Jan 1;39(1):17-29.
Více informací ZDE
Topical Betamethasone Valerate As a Prophylactic Agent to Prevent Acute Radiation Dermatitis in Head and Neck Malignancies: A Randomized, Open-Label, Phase 3 Trial.
Int J Radiat Oncol Biol Phys. 2021 Jan 1;109(1):151-160.
Více informací ZDE
PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol. 2021 Feb;22(2):223-234.
Více informací ZDE
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial.
Lancet Oncol. 2021 Feb;22(2):235-245.
Více informací ZDE
Endoscopic surgery compared with intensity-modulated radiotherapy in resectable locally recurrent nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial.
Lancet Oncol. 2021 Mar;22(3):381-390.
Více informací ZDE
4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial.
Lancet Oncol. 2021 Mar;22(3):332-340.
Více informací ZDE
Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: Results From the FLAME Randomized Phase III Trial.
J Clin Oncol. 2021 Mar 1;39(7):787-796.
Více informací ZDE
Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 Trial.
Int J Radiat Oncol Biol Phys. 2021 Mar 15;109(4):975-986.
Více informací ZDE
Breast-Conserving Surgery Followed by Partial or Whole Breast Irradiation: Twenty-Year Results of a Phase 3 Clinical Study.
Int J Radiat Oncol Biol Phys. 2021 Mar 15;109(4):998-1006.
Více informací ZDE
Primary Tumor Resection Plus Chemotherapy Versus Chemotherapy Alone for Colorectal Cancer Patients With Asymptomatic, Synchronous Unresectable Metastases (JCOG1007; iPACS): A Randomized Clinical Trial.
J Clin Oncol. 2021 Apr 1;39(10):1098-1107.
Více informací ZDE
Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial.
JAMA Oncol. 2021 Apr 1;7(4):555-563.
Více informací ZDE
70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age.
Lancet Oncol. 2021 Apr;22(4):476-488.
Více informací ZDE
IOERT versus external beam electrons for boost radiotherapy in stage I/II breast cancer: 10-year results of a phase III randomized study.
Breast Cancer Res. 2021 Apr 13;23(1):46.
Více informací ZDE
Palliative radiotherapy after oesophageal cancer stenting (ROCS): a multicentre, open-label, phase 3 randomised controlled trial.
Lancet Gastroenterol Hepatol. 2021 Apr;6(4):292-303.
Více informací ZDE
Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial.
J Clin Oncol. 2021 Apr 10;39(11):1234-1242.
Více informací ZDE
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.
N Engl J Med. 2021 Apr 1;384(13):1191-1203.
Více informací ZDE
Once Daily Versus Twice Daily External Beam Accelerated Partial Breast Irradiation: A Randomized Prospective Study.
Int J Radiat Oncol Biol Phys. 2021 Apr 1;109(5):1296-1300.
Více informací ZDE
Intensity Modulated Radiation Therapy (IMRT) With Simultaneously Integrated Boost Shortens Treatment Time and Is Noninferior to Conventional Radiation Therapy Followed by Sequential Boost in Adjuvant Breast Cancer Treatment: Results of a Large Randomized Phase III Trial (IMRT-MC2 Trial).
Int J Radiat Oncol Biol Phys. 2021 Apr 1;109(5):1311-1324.
Více informací ZDE
Radical Hemithoracic Radiotherapy Versus Palliative Radiotherapy in Non-metastatic Malignant Pleural Mesothelioma: Results from a Phase 3 Randomized Clinical Trial.
Int J Radiat Oncol Biol Phys. 2021 Apr 1;109(5):1368-1376.
Více informací ZDE
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
Lancet Oncol. 2021 Apr;22(4):450-462.
Více informací ZDE
Two-year toxicity of simultaneous integrated boost in hypofractionated prone breast cancer irradiation: Comparison with sequential boost in a randomized trial.
Radiother Oncol. 2021 May;158:62-66.
Více informací ZDE
Photobiomodulation therapy for the prevention of acute radiation dermatitis in head and neck cancer patients (DERMISHEAD trial).
Radiother Oncol. 2021 May;158:268-275.
Více informací ZDE
Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial.
Lancet Oncol. 2021 May;22(5):716-726.
Více informací ZDE
Extended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer: Early Oncological Outcomes from a Randomized Phase 3 Trial.
Eur Urol. 2021 May;79(5):595-604.
Více informací ZDE
Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.
Lancet Oncol. 2021 May;22(5):702-715.
Více informací ZDE
Intraoperative irradiation for early breast cancer (ELIOT): long-term recurrence and survival outcomes from a single-centre, randomised, phase 3 equivalence trial.
Lancet Oncol. 2021 May;22(5):597-608.
Více informací ZDE
Phase 3 Randomized Trial of Prophylactic Cranial Irradiation With or Without Hippocampus Avoidance in SCLC (NCT01780675).
J Thorac Oncol. 2021 May;16(5):840-849.
Více informací ZDE
Neck Dissections Based on Sentinel Lymph Node Navigation Versus Elective Neck Dissections in Early Oral Cancers: A Randomized, Multicenter, and Noninferiority Trial.
J Clin Oncol. 2021 Jun 20;39(18):2025-2036.
Více informací ZDE
Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial.
J Clin Oncol. 2021 Jun 20;39(18):1995-2004.
Více informací ZDE
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study.
Lancet Oncol. 2021 Jun;22(6):813-823.
Více informací ZDE
Phase 3 Multi-Center, Prospective, Randomized Trial Comparing Single-Dose 24 Gy Radiation Therapy to a 3-Fraction SBRT Regimen in the Treatment of Oligometastatic Cancer.
Int J Radiat Oncol Biol Phys. 2021 Jul 1;110(3):672-679.
Více informací ZDE
Patient-Reported Outcomes From a Phase 3 Randomized Controlled Trial Exploring Optimal Sequencing of Short-Term Androgen Deprivation Therapy With Prostate Radiation Therapy in Localized Prostate Cancer.
Int J Radiat Oncol Biol Phys. 2021 Jul 15;110(4):1101-1113.
Více informací ZDE
Comparison of Radiation With or Without Concurrent Trastuzumab for HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy: A Phase III Clinical Trial.
J Clin Oncol. 2021 Jul 20;39(21):2367-2374.
Více informací ZDE
Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2/3 trial.
Lancet Oncol. 2021 Jul;22(7):1023-1033.
Více informací ZDE
Dose-escalated intensity-modulated radiotherapy in patients with locally advanced laryngeal and hypopharyngeal cancers: ART DECO, a phase III randomised controlled trial.
Eur J Cancer. 2021 Aug;153:242-256.
Více informací ZDE
Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non-Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy: The Phase 3 PORT-C Randomized Clinical Trial.
JAMA Oncol. 2021 Aug 1;7(8):1178-1185.
Více informací ZDE
Long-Term Outcomes of Radical Radiation Therapy with Hypoxia Modification with Biomarker Discovery for Stratification: 10-Year Update of the BCON (Bladder Carbogen Nicotinamide) Phase 3 Randomized Trial (ISRCTN45938399).
Int J Radiat Oncol Biol Phys. 2021 Aug 1;110(5):1407-1415.
Více informací ZDE
Randomized Study on Dose Escalation in Definitive Chemoradiation for Patients With Locally Advanced Esophageal Cancer (ARTDECO Study).
J Clin Oncol. 2021 Sep 1;39(25):2816-2824.
Více informací ZDE
Radiation and Androgen Deprivation Therapy With or Without Docetaxel in the Management of Nonmetastatic Unfavorable-Risk Prostate Cancer: A Prospective Randomized Trial.
J Clin Oncol. 2021 Sep 10;39(26):2938-2947.
Více informací ZDE
Short Androgen Suppression and Radiation Dose Escalation in Prostate Cancer: 12-Year Results of EORTC Trial 22991 in Patients With Localized Intermediate-Risk Disease.
J Clin Oncol. 2021 Sep 20;39(27):3022-3033.
Více informací ZDE
Quality of life after simultaneously integrated boost with intensity-modulated versus conventional radiotherapy with sequential boost for adjuvant treatment of breast cancer: 2-year results of the multicenter randomized IMRT-MC2 trial.
Radiother Oncol. 2021 Sep 1;163:165-176.
Více informací ZDE
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
N Engl J Med. 2021 Sep 16;385(12):1091-1103.
Více informací ZDE
Randomized Phase III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small-Cell Lung Cancer (PREMER): A GICOR-GOECP-SEOR Study.
J Clin Oncol. 2021 Oct 1;39(28):3118-3127.
Více informací ZDE
Prognostic factor analysis and long-term results of the TAX 323 (EORTC 24971) study in unresectable head and neck cancer patients.
Eur J Cancer. 2021 Oct;156:109-118.
Více informací ZDE
Five-Year Longitudinal Analysis of Patient-Reported Outcomes and Cosmesis in a Randomized Trial of Conventionally Fractionated Versus Hypofractionated Whole-Breast Irradiation.
Int J Radiat Oncol Biol Phys. 2021 Oct 1;111(2):360-370.
Více informací ZDE
Quality of life after simultaneously integrated boost with intensity-modulated versus conventional radiotherapy with sequential boost for adjuvant treatment of breast cancer: 2-year results of the multicenter randomized IMRT-MC2 trial.
Radiother Oncol. 2021 Oct;163:165-176.
Více informací ZDE
Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II.
J Clin Oncol. 2021 Nov 10;39(32):3623-3632.
Více informací ZDE
Randomized Trial of Radiation Therapy With Weekly Cisplatin or Cetuximab in Low-Risk HPV-Associated Oropharyngeal Cancer (TROG 12.01) - A Trans-Tasman Radiation Oncology Group Study.
Int J Radiat Oncol Biol Phys. 2021 Nov 15;111(4):876-886.
Více informací ZDE
Involved-Field Radiation Therapy Prevents Recurrences in the Early Stages of Hodgkin Lymphoma in PET-Negative Patients After ABVD Chemotherapy: Relapse Analysis of GHSG Phase 3 HD16 Trial.
Int J Radiat Oncol Biol Phys. 2021 Nov 15;111(4):900-906.
Více informací ZDE
Preoperative radiotherapy 5 × 5 Gy and short versus long interval between surgery for resectable rectal cancer: 10-Year follow-up of the randomised controlled trial.
Radiother Oncol. 2021 Nov;164:268-274.
Více informací ZDE
Randomized Phase III Trial Evaluating Radiation Following Surgical Excision for Good-Risk Ductal Carcinoma In Situ: Long-Term Report From NRG Oncology/RTOG 9804.
J Clin Oncol. 2021 Nov 10;39(32):3574-3582.
Více informací ZDE
Late Toxicity After Adjuvant Conventional Radiation Versus Image-Guided Intensity-Modulated Radiotherapy for Cervical Cancer (PARCER): A Randomized Controlled Trial.
J Clin Oncol. 2021 Nov 20;39(33):3682-3692.
Více informací ZDE
Quality of life in patients with locally advanced head and neck cancer treated with concurrent chemoradiation with cisplatin and nimotuzumab versus cisplatin alone - Additional data from a phase 3 trial.
Oral Oncol. 2021 Nov;122:105517.
Více informací ZDE
Optimizing Treatment in Intermediate-Risk Prostate Cancer: Secondary Analysis of a Randomized Phase 3 Trial.
Int J Radiat Oncol Biol Phys. 2021 Nov 1;111(3):732-740.
Více informací ZDE
Phase 3 Randomized Trial of Topical Steroid Versus Placebo for Prevention of Radiation Dermatitis in Patients With Head and Neck Cancer Receiving Chemoradiation.
Int J Radiat Oncol Biol Phys. 2021 Nov 1;111(3):794-803.
Více informací ZDE
Low-Dose-Rate versus High-Dose-Rate intracavitary brachytherapy in cervical cancer - Final Results of a Phase III randomized trial.
Brachytherapy. 2021 Nov-Dec;20(6):1146-1155.
Více informací ZDE
Impact of Hypofractionated Radiotherapy on Patient-reported Outcomes in Prostate Cancer: Results up to 5 yr in the CHHiP trial (CRUK/06/016).
Eur Urol Oncol. 2021 Dec;4(6):980-992.
Více informací ZDE
